Rapport Therapeutics reported robust Phase IIa data for RAP-219, an experimental drug targeting TARPγ8-specific AMPA receptors, showing a 78% median reduction in clinical seizures in patients with drug-resistant focal onset seizures. The trial also demonstrated a significant decrease in electrographic seizure markers, reinforcing the drug's efficacy. Following this success, the company plans to initiate Phase III trials, with the market valuation doubling shortly after announcement.